OR Oncology Reports 1021-335X 1791-2431 D.A. Spandidos 10.3892/or.2015.3757 or-33-04-1723 Articles Inhibition of c-Myc by let-7b mimic reverses mutidrug resistance in gastric cancer cells YANGXIAOJUN1* CAIHUI1* LIANGYUHE2* CHENLIN3 WANGXIANGDONG2 SIRUOHUANG1 QUKUNPENG1 JIANGZEBIN1 MABINGQIANG1 MIAOCHANGFENG1 LIJING1 WANGBIN1 GAOPENG1 Department of General Surgery, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China Department of General Surgery, the People’s Hospital of Baoji City, Baoji, Shaanxi 721000, P.R. China Department of Infectious Disease, the First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China Correspondence to: Dr Peng Gao, Department of General Surgery, Gansu Provincial Hospital, 160 Donggang West Road Lanzhou, Gansu 730000, P.R. China, E-mail: gaopenglz@aliyun.com

Contributed equally

 4 2015 28 01 2015 33 4 1723 1730 02 10 2014 23 12 2014 Copyright © 2015, Spandidos Publications 2015 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

Chemotherapy is one of the few effective choices for patients with advanced or recurrent gastric cancer (GC). However, the development of mutidrug resistance (MDR) to cancer chemotherapy is a major obstacle to the effective treatment of advanced GC. Additionally, the mechanism of MDR remains to be determined. In the present study, we tested IC50 of cisplating (DDP), vincristine (VCR) and 5-fluorouracil (5-FU) in SGC7901, SGC7901/DDP and SGC7901/VCR gastric cancer cells using an MTT assay. The expression of let-7b and c-Myc in these cells was detected by qPCR and western blot analysis. The relationship between let-7b and c-Myc was explored using a luciferase reporter assay. Transfection of let-7b mimic or inhibitor was used to confirm the effect of let-7b on drug sensitivity in chemotherapy via the regulation of c-Myc expression. We found that the expression of let-7b was lower in chemotherapy-resistant SGC7901/DDP and SGC7901/VCR gastric cancer cells than that in chemotherapy-sensitive SGC7901 cells. By contrast, the expression of c-Myc was higher in SGC7901/DDP and SGC7901/VCR cells than that in SGC7901 cells. Furthermore, we confirmed that let-7b suppresses c-Myc gene expression at the mRNA and protein levels in a sequence-specific manner, while transfection of let-7b mimic increases drug sensitivity in chemotherapy-resistant SGC7901/DDP and SGC7901/VCR cells by targeting downregulation of c-Myc. In SGC7901 drug-sensitive cells, however, the sensitivity of chemotherapy was significantly decreased following let-7b inhibitor transfection. The present study results demonstrated that let-7b increases drug sensitivity in chemotherapy-resistant SGC7901/DDP and SGC7901/VCR gastric cancer cells by targeting the downregulation of c-Myc and that, let-7b mimic reverses MDR by promoting cancer stem cell differentiation controlled by double-negative autoregulatory loops (Lin28/let-7 and Myc/let-7) and a double-positive autoregulatory loop (Lin28/Lin28B/Myc) existing in GC cells, which remains to be confirmed.

 gastric cancer mutidrug resistance c-Myc let-7b Introduction

Gastric cancer (GC) is a leading disease in Eastern Asia (including South Korea, Japan and China). The incidence and mortality of GC in East Asian regions rank, respectively, second and third among the most common types of cancer worldwide (1,2). According to World Health Organization statistics, there were 988,000 new cases of GC worldwide and 736,000 deaths in 2008. Approximately 60% of the cases were identified in East Asia (mainly China). In China, approximately two-thirds of patients develop advanced or metastatic disease, and >50% have recurrent disease following curative surgery (3–5). For these patients, chemotherapy remains the most effective treatment of choice. However, the development of mutidrug resistance (MDR) to cancer chemotherapy is a major obstacle to the effective treatment of advanced GC (6). Moreover, the mechanism of MDR remains obscure.

c-Myc gene is crucial in gastric carcinogenesis. The c-Myc protein is a transcription factor that regulates a large series of downstream genes. An association between c-Myc deregulation and GC has been previously demonstrated (7). c-Myc overexpression has been described in >40% of GC (7). It encodes a helix-loop-helix leucine zipper transcription factor that dimerizes with its partner protein, Max, to transactivate gene expression (8,9). c-Myc regulates several large gene families resulting in coordinated changes in cell proliferation and metabolism. c-Myc stimulates genes involved in protein biosynthesis, cancer metabolism, transcription factors, cell cycle and some microRNAs, while inhibiting the expression of other microRNAs and some tumor suppressor genes (8). The pleiotropic effects of c-Myc expression occur at the molecular and cellular level and affect almost every activity of cell life (10).

In vivo studies have demonstrated that a single low-dose cisplatin treatment results in tumour growth retardation and a 2-fold elevation in the level of c-Myc expression (11,12). This reproducible elevation in the expression of c-Myc is mirrored by reports of analysis conducted on freshly isolated colon carcinoma tissues from patients with failed cisplatin therapy (13). Although these data demonstrate that relatively low doses of cisplatin can evoke a significant increase in c-Myc expression, it is premature to suggest there is a direct link between use of cisplatin and c-Myc-modulated chemoresistance. Clearly, the mechanism for chemoresistance remains to be investigated.

MicroRNAs (miRNAs) are a group of small RNAs, which are single-stranded and consist of 19–25 nucleotides. They do not code for any protein or peptide; however, they regulate gene expression by various mechanisms. The aberrant miRNA expression and its correlation with the development and progression of cancers is an emerging field (14,15). Some miRNAs regulate the formation of cancer stem cells and the acquisition of epithelial-mesenchymal transition, which are critically associated with drug resistance (16,17). Moreover, some miRNAs target genes associated with drug sensitivity, resulting in the altered sensitivity of cancer cells to anti-cancer drugs. Findings of previous studies have also shown that the knockdown or re-expression of specific miRNAs by synthetic antisense oligonucleotides or pre-miRNAs induced drug sensitivity, leading to increased inhibition of cancer cell growth, invasion, and metastasis (18,19). Those results suggested that specific targeting of miRNAs by different approaches potentially open new avenues for cancer treatment by overcoming drug resistance, thereby improving the outcome of cancer therapy.

The let-7 miRNAs are a family of 12 sequence-associated miRNAs that are distributed over eight genomic clusters and are often downregulated in cancers (20). The let-7 miRNAs function as tumor suppressors through the silencing of key oncogenes, such as RAS and MYC (21,22). Findings on ovarian cancer showed that let-7i expression was significantly reduced in chemotherapy-resistant patients and in vitro reduction of let-7i expression was associated with the resistance of ovarian and breast cancer cells to cisplatin (23). By investigating drug resistance to cisplatin and 5-fluorouracil in 90 patients with GC and comparing miRNA expression of patients before and after chemotherapy, Kim et al (24) found that a high expression of let-7g indicated sensitivity to chemotherapy.

We found that c-Myc may serve as a target gene of let-7b through Targetscan and Pictar bioinformatics software. In this study, we detected the expression of let-7b and c-Myc in SGC7901 and drug-resistant SGC7901/VCR and SGC7901/ DDP GC cell lines. The aim was to determine whether let-7b regulates the sensitivity of chemotherapy to mutidrugs in GC by possibly targeting c-Myc, and to confirm our hypothesis that inhibition of c-Myc by let-7b reverses MDR in GC cells.

 Materials and methods Cell culture

The human SGC7901 gastric cancer cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Its drug-resistant SGC7901/DDP and SGC7901/VCR cells were purchased from the Keygen Biotech Development Co., Ltd. (Nanjing, China). The cell lines were cultured in RPMI-1640 (Gibco, Grand Island, NY, USA) medium with 10% fetal bovine serum (Sijiqing, Hangzhou, China), and maintained in a humidified incubator at 37°C with an atmosphere of 5% CO2.

 Cell viability and drug sensitivity assay

The SGC7901, SGC7901/VCR, SGC7901/DDP cells were transfected with let-7b mimic or inhibitor and control mimic. The transfected cells were seeded in 96-well plates for 24 h and then treated with different concentrations of cisplatin (DDP) (Qilu Pharmaceutical Co., Ltd., Shandong, China), 5-fluorouracil (5-FU) (KingYork Group Co., Ltd., Tianjin, China) and vincristine (VCR) (HuaLian Pharmaceutical Co., Ltd., Shanghai, China). After 48 h, the cell viability was evaluated by the MTT assay according to the manual. Absorbance at 490 nm was measured on an ELISA reader. Dose-effect curves of anticancer drugs were drawn on semi-logarithm coordinate paper and IC50 values were determined. Each experiment was conducted in triplicate and repeated three times.

 Quantitative PCR

Total RNA was extracted using TRIzol reagent (Invitrogen Inc., Carlsbad, CA, USA) and reverse-transcribed using a high capacity RNA-cDNA kit (Applied Biosystems Inc., Foster City, CA, USA). cDNA was quantified on an ABI Prism 7900 sequence detection system (Applied Biosystems Inc.). PCR was performed using Power SYBR-Green PCR master mix (Applied Biosystems Inc.). The U6 small nuclear RNA was used as an internal control for let-7b. The GAPDH was used as an internal control for c-Myc. Primer sequences used are listed in Table I.

 Western blot analysis

Cells were lysed in mammalian protein extraction reagent (Pierce Inc., Rockford, IL, USA) with protease inhibitor cocktail (Sigma, St. Louis, MO, USA). Following centrifugation at 5,000 × g for 15 min at 4°C, the protein concentration was measured with a BCA protein assay kit (Pierce Inc., 23227). Total protein (15 μg) was separated by 10% SDS-PAGE under denaturing conditions and transferred to PVDF membranes (Millipore Inc., Billerica, MA, USA). Membranes were blocked in 5% non-fat milk (Bio-Rad, Hercules, CA, USA) and then incubated with the c-Myc antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). After incubation with a secondary antibody conjugated with HRP (Amersham Biosciences Inc., Uppsala, Sweden) together with an HRP-conjugated primary antibody for β-actin (Sigma), immunoreactive proteins were visualized using the LumiGLO chemiluminescent substrate (Cell Signaling Technology Inc., Danvers, MA, USA). Densitometric analyses were performed using Scion Image software.

 Luciferase reporter assay

The DNA encoding 3′UTR of c-Myc was PCR-amplified from human genomic DNA and cloned downstream of firefly luciferase reporter gene in pGL3-control plasmid (Promega Corp., Madison, WI, USA). SGC7901 gastric cancer cells were plated in a 24-well plate 24 h prior to transfection at 50% confluence. Let-7b mimic (30 nM) or control mimic (Ambion Inc., Austin, TX, USA) were transfected using Lipofectamine RNAiMAX (Invitrogen Inc.). After 24 h post-transfection, 0.125 μg of reporter vector or empty vector were transfected using FuGENE6 transfection reagent (Roche Inc., Basel, Switzerland). After 48-h reporter vector transfection, the cells were collected, and reporter assays were performed using a dual luciferase reporter assay system (Promega Corp.).

 Transfection of let-7b mimic and inhibitor oligonucleotides

Pre-miR miRNA precursor and control oligos were purchased from Ambion Inc. miRCURY LNA miRNA inhibitors and control oligos were purchased from Exiqon (Vedbaek, Denmark). Transfections were performed using the Lipofectamine RNAiMAX transfection reagent (Invitrogen Inc.), and then cells were incubated in the medium containing the transfection mixture for 24–48 h.

 Statistical analysis

Data were expressed as mean ± SD. One-way ANOVA followed by Bonferroni correction was used to compare the data among three or more groups, followed by the Student’s t-test. Statistical analyses were performed using the SPSS 15.0 software package for Windows (SPSS Inc.., Chicago, IL, USA). P<0.05 was considered significant.

 Results IC<sub>50</sub> of DDP, VCR and 5-FU in SGC7901, SGC7901/DDP and SGC7901/VCR gastric cancer cells

SGC7901, SGC7901/VCR and SGC7901/DDP cells were seeded in 96-well plates for 24 h and then treated with different concentrations of DDP, VCR and 5-FU. After 48 h, the cell viability was evaluated by the MTT assay according to the manual. Absorbance at 490 nm was measured on an ELISA reader. Dose-effect curves of anticancer drugs were drawn on semi-logarithm coordinate paper and IC50 values were determined (Fig. 1A). IC50 of DDP in SGC7901, SGC7901/DDP and SGC7901/VCR cells were 0.23, 2.98 and 2.14 μM/l, respectively. IC50 of VCR in SGC7901, SGC7901/DDP and SGC7901/VCR cells were 0.35, 0.77 and 1.18 μM/l, respectively. IC50 of 5-FU in SGC7901, SGC7901/DDP and SGC7901/VCR cells were 0.32, 1.62 and 1.42 μM/l, respectively.

 Expression of let-7b and c-Myc in SGC7901, SGC7901/ DDP and SGC7901/VCR gastric cancer cells

To investigate the potential role of let-7b on MDR in GC, the expression of let-7b in SGC7901, SGC7901/DDP and SGC7901/VCR cells was evaluated by qPCR. A significant difference was observed between SGC7901 and the drug-resistant SGC7901/DDP and SGC7901/VCR cells (Fig. 1B). The expression of c-Myc mRNA was increased in SGC7901/DDP and SGC7901/VCR cells compared with that of SGC7901 cells (Fig. 1B). To confirm this phenomenon, we also performed western blot analysis for c-Myc protein. The protein levels of c-Myc were higher in SGC7901/DDP and SGC7901/VCR cells than that in SGC7901 cells (Fig. 1C and D). Taken together, we demonstrated that there is a potential correlation between let-7b and c-Myc.

 Let-7b directly targets the 3′UTR of c-Myc

We predicted that there was a conserved let-7 binding site in the c-Myc 3′UTR by TargetScan (Fig. 2A). This hypothesis was confirmed experimentally. To determine whether let-7b regulation to c-Myc gene depends on its binding sites of 3′UTR sequences on the target genes, we constructed reporter plasmids with wild-type or mutant let-7b binding sites from 3′UTR of c-Myc gene inserted in the downstream sequence of the luciferase gene. A reporter assay was performed by co-transfecting SGC7901/DDP cells with wild-type or mutant reporter plasmids and let-7b mimic or control oligos. Let-7b potently decreased the luciferase activity of wild-type reporter plasmid examined in this study, whereas it had no effect on the mutant forms (Fig. 2B). We concluded that let-7b suppressed c-Myc gene expression in a sequence-specific manner and the suppression depends on let-7b binding sites within 3′UTR sequences of the c-Myc genes.

 Transfection of let-7b mimic downregulates the expression of c-Myc and increases the sensitivity of chemotherapy in SGC7901/DDP and SGC7901/VCR cells

To investigate whether let-7b could regulate c-Myc expression, let-7b mimic and control mimic, respectively, were transfected in SGC7901/DDP and SGC7901/VCR cells. The expression of let-7b and c-Myc in the two cell lines was detected by qPCR. As shown in Fig. 3A, the expression of let-7b was significantly higher in let-7b mimic-transfected cells than that in control mimic-transfected cells. However, the expression of c-Myc was significantly lower in let-7b mimic-transfected cells than that in the control mimic-transfected cells. From the results of western blotting, we found that transfection of let-7b mimic significantly downregulated the expression of c-Myc protein in the two cells (Fig. 3B). Therefore, we concluded that let-7b suppresses c-Myc gene expression at the mRNA and protein levels.

To determine whether transfection of let-7b mimic affects cell proliferation in SGC7901/DDP and SGC7901/VCR cells, metabolic activity at 24, 48 and 72 h after transfection was determined by MTT assay. The cell viability was reduced significantly in the two cells after transfection with the let-7b mimic at 48 and 72 h as compared with the control mimic (Fig. 3C, P<0.05).

To explore the role of c-Myc on the sensitivity of chemotherapy in GC cells, SGC7901/VCR and SGC7901/DDP cells were transfected with let-7b or control mimic. The transfected cells were seeded in 96-well plates for 24 h and then treated with different concentrations of DDP, VCR and 5-FU. After 48 h, the cell viability was evaluated by the MTT assay according to the manual, dose-effect curves of anticancer drugs were drawn on semi-logarithm coordinate paper and IC50 values were determined. As shown in Fig. 3D, the IC50 valus of DDP, VCR and 5-FU were 2.13±0.18, 0.54±0.08 and 1.23±0.09 μM/l in let-7b mimic-transfected SGC7901/DDP cells, and were 2.76±0.22, 0.81±0.12 and 1.57±0.16 μM/l in control mimic-transfected SGC7901/DDP cells. For SGC7901/ VCR cells, the IC50 of DDP, VCR and 5-FU were 1.71±0.19, 1.41±0.11 and 1.11±0.05 μM/l in let-7b mimic-transfected cells, and were 2.23±0.11, 1.69±0.09 and 1.39±0.12 μM/l in control mimic transfected cells, respectively. Thus, the two drug-resistant GC cells showed the sensitivity of chemotherapy to be significantly increased in let-7b mimic-transfected cells at the 3rd day after transfection.

 Transfection of let-7b inhibitor upregulates the expression of c-Myc and decreases the sensitivity of chemotherapy in SGC7901 cells

For loss-of-function experiments, let-7b inhibitor was used to block endogenous let-7b expression in SGC7901 cell lines. The expression of let-7b and c-Myc was detected by qPCR. As shown in Fig. 4A, the expression of let-7b was significantly lower in let-7b inhibitor-transfected cells than that in control mimic-transfected cells. However, the expression of c-Myc was significantly higher in let-7b inhibitor-transfected cells than that in control mimic-transfected cells. From the results of western blotting, we found that the transfection of let-7b inhibitor significantly increased the expression of c-Myc protein in SGC7901 cells (Fig. 4B). We also confirmed that transfection of let-7b inhibitor enhances SGC7901 cell proliferation at 48 and 72 h after transfection by MTT assay (Fig. 4C, P<0.05).

The sensitivity of chemotherapy in SGC7901 cells was also detected by MTT assay following transfection with let-7b inhibitor or control mimic. As shown in Fig. 4D, the IC50 values of DDP, VCR and 5-FU were 0.44±0.06, 0.53±0.07 and 0.67±0.08 μM/l in let-7b inhibitor-transfected SGC7901 cells, and were 0.26±0.04, 0.31±0.04 and 0.41±0.04 μM/in control mimic-transfected cells, respectively. We demonstrated that in drug-sensitive GC cells, the sensitivity of chemotherapy was significantly decreased following let-7b inhibitor transfection.

 Discussion

Chemotherapy is an important therapeutic strategy for advanced or recurrent gastric cancer (GC) treatment. However, chemotherapy fails to eliminate all tumor cells because of intrinsic or acquired MDR, which is the most common cause of tumor recurrence (25,26), and the greatest obstacle for the effective treatment of GC (6). The underlying mechanisms of cellular resistance in cancer cells to these DNA-damaging anticancer drugs have been broadly explored, but have not been fully characterized (27,28). P-gp was the first molecule identified as a modulator of MDR. Subsequently, various other molecules were shown to be involved, including transporters that eject anticancer drugs from cells, such as MDR-associated protein (MRP) (29), genes regulating apoptosis, such as p53 (30), telomere-binding protein, such as TRF2(31), RhoE GTPase (32) and transcription factors, such as CDX2 (33) and c-Myc (13). miRNAs have also beeen considered to be involved in the field of cancer MDR investigations. miRNAs are a class of small, non-coding RNA molecules that repress protein expression through imperfect binding to sequences in the 3′UTR of target mRNAs, Seven miRNAs were found to be significantly and differentially expressed in tumors from platinum-sensitive vs. platinum-resistant patients. These seven miRNAs included miR-27a, miR-23a, miR-30c, let-7g, miR-199a-3p, miR-378 and miR-625, which were overexpressed in platinum-resistant patients (34). Results of a recent study suggested that miRNA-200c regulates the sensitivity of chemotherapy to cisplatin (DDP) in SGC7901/DDP gastric cancer cells by directly targeting RhoE (32). Chen et al (35) transfected miRNA-200c into SGC7901/DDP gastric cancer cells, which increased sensitivity to DDP, 5-fluorouracil, paclitaxel and doxorubicin.

In the present study, we found that the expression of let-7b was lower in chemotherapy-resistant SGC7901/DDP and SGC7901/ VCR gastric cancer cells than that in chemotherapy-sensitive SGC7901 cells. By contrast, the expression of c-Myc was higher in SGC7901/DDP and SGC7901/VCR cells than that in SGC7901 cells. Using TargetScan and luciferase reporter assay, we confirmed that let-7b suppresses c-Myc gene expression in a sequence-specific manner and this suppression depends on let-7b binding sites within 3′UTR sequences of the c-Myc genes. Furthermore, we have demonstrated that transfection of let-7b mimic increases drug sensitivity in chemotherapy-resistant SGC7901/DDP and SGC7901/VCR cells by targeting the downregulation of c-Myc. For loss-of-function experiments, the results suggest that in drug-sensitive SGC7901 cells, the sensitivity of chemotherapy was significantly decreased after let-7b inhibitor transfection.

An increasing number of reports have suggested that let-7 is poorly expressed in a variety of human tumors and a reduced let-7 level results in the overexpression of let-7-responsive genes in tumors, including CyclinD, RAS, Myc and Lin28/Lin28B (36–39). According to our previous report, a double-negative feedback regulating loop of Lin28 and let-7 exists in tumor cells and controls ALDH1+ cancer stem cells (40). let-7 interacts with two iPS genes, Myc and Lin28, and these autoregulatory loops of let-7/Myc (41) and let-7/Lin28 (40) may control stem cell self-renewal and differentiation. High levels of Lin28 and Myc or a low level of let-7 may promote the conversion of epithelial cells to a more undifferentiated stage and maintain tumor cells in this stem-like stage (40,42). A recent study found that Lin28B enhances n-Myc levels and induces neuroblastoma, suggesting that n-Myc is a key target of Lin28B (43). Moreover, the c-Myc and n-Myc oncogenes are positive regulators of Lin28 and Lin28B, respectively (44,45).

Emerging evidence suggests that cancer stem cells (CSCs) may play critical roles in drug resistance and ultimately recurrence (46–50). The present findings together with those of previous reports (40,41,43–45) support a model in which double-negative autoregulatory loops (Lin28/let-7 and Myc/let-7) and a double-positive autoregulatory loop (Lin28/Lin28B/Myc) existing in GC cells may control cancer stem cell differentiation and regulate MDR (Fig. 5).

In conclusion, the present study results have demonstrated that, let-7b increases drug sensitivity in chemotherapy-resistant SGC7901/DDP and SGC7901/VCR gastric cancer cells by targeting downregulation of c-Myc and that, let-7b mimic reverses MDR by promoting cancer stem cell differentiation controlled by double-negative autoregulatory loops (Lin28/ let-7 and Myc/let-7) and a double-positive autoregulatory loop (Lin28/ Lin28B/Myc) existing in GC cells, which remains to be confirmed. These results suggest that let-7b plays key roles in MDR of GC. By downregulating Lin28 and c-Myc and promoting cancer stem cell differentiation, let-7b may function as a chemotherapy enhancer in GC. This role in regulating GC cell MDR signifies an opportunity to develop novel cancer therapies. Therefore, it is presumed that enforced expression of let-7b may improve the chemotherapy efficiency of patients with GC with a low let-7b expression.

 Acknowledgements

This study was supported, in whole or in part, by GWGL2013-47(HC), and Natural Science Foundation of Gansu Province (145RJZA117, HC). We are greatly indebted to Dr Youcheng Zhang (Lanzhou University Second Hospital) and Lin Zhang (University of Pennsylvania School of Medicine) for the technical assistance.

 References LeeJHKimKMCheongJHNohSHCurrent management and future strategies of gastric cancerYonsei Med J53248257201210.3349/ymj.2012.53.2.248223188103282952 HudlerPGenetic aspects of gastric cancer instabilitySci World J2012761909201210.1100/2012/761909 VerdecchiaACorazziariIGattaGLisiDFaivreJFormanDEUROCARE Working GroupExplaining gastric cancer survival differences among European countriesInt J Cancer109737741200410.1002/ijc.2004714999783 BonenkampJJHermansJSasakoMExtended lymphnode dissection for gastric cancerN Engl J Med340908914199910.1056/NEJM19990325340120210089184 KanekoSYoshimuraTTime trend analysis of gastric cancer incidence in Japan by histological types, 1975–1989Br J Cancer84400405200110.1054/bjoc.2000.1602111614072363747 FanDLiuXNew progresses in researches on multidrug resistance in gastric cancerChin J Digest2077782000 MilneANSitarzRCarvalhoRCarneiroFOfferhausGJEarly onset gastric cancer: on the road to unraveling gastric carcinogenesisCurr Mol Med71528200710.2174/15665240777994050317311530 EilersMEisenmanRNMyc’s broad reachGenes Dev2227552766200810.1101/gad.1712408189230742751281 HerkertBEilersMTranscriptional repression: the dark side of mycGenes Cancer1580586201010.1177/1947601910379012 MillerMDThomasSDIslamAMuenchDSedorisKC-Myc and cancer metabolismClin Cancer Res1855465553201210.1158/1078-0432.CCR-12-0977230713563505847 WalkerTLWhiteJDEsdaleWJBurtonMADeCruzEETumour cells surviving in vivo cisplatin chemotherapy display elevated cmyc expressionBr J Cancer73610614199610.1038/bjc.1996.10586050942074343 MarazziLParodiMTMartinoDDFerrariSToniniGPCoordinate change of c-myc, transferrin receptor and H3 gene expression precedes induction of haemoglobin-producing cells of the leukaemia K562 cell line treated with cisdiamminedichlo-roplatinum IIAnticancer Res1194795219912064352 Kashani-SabetMLuYLeongLHaedickeKScanlonKJDifferential oncogene amplification in tumour cells from a patient treated with cisplatin and 5-FUEur J Cancer26383390199010.1016/0277-5379(90)90238-O2141497 VandenboomTGIILiYPhilipPASarkarFHMicroRNA and cancer: tiny molecules with major implicationsCurr Genomics997109200810.2174/138920208784139555 IorioMVCroceCMMicroRNAs in cancer: small molecules with a huge impactJ Clin Oncol2758485856200910.1200/JCO.2009.24.0317198845362793003 PeterMERegulating cancer stem cells the miR wayCell Stem Cell646201010.1016/j.stem.2009.12.00620085735 AdamLZhongMChoiWmiR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapyClin Cancer Res1550605072200910.1158/1078-0432.CCR-08-224519671845 BourguignonLYSpevakCCWongGXiaWGiladEHyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cellsJ Biol Chem2842653326546200910.1074/jbc.M109.027466196332922785342 BlowerPEChungJHVerducciJSMicroRNAs modulate the chemosensitivity of tumor cellsMol Cancer Ther719200810.1158/1535-7163.MCT-07-057318187804 RoushSSlackFJThe let-7 family of microRNAsTrends Cell Biol18505516200810.1016/j.tcb.2008.07.00718774294 LeeYSDuttaAThe tumor suppressor microRNA let-7 represses the HMGA2 oncogeneGenes Dev2110251030200710.1101/gad.1540407174379911855228 KumarMSLuJMercerKLGolubTRJacksTImpaired microRNA processing enhances cellular transformation and tumorigenesisNat Genet39673677200710.1038/ng200317401365 YangNKaurSVoliniaSMicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancerCancer Res681030710314200810.1158/0008-5472.CAN-08-1954190748992762326 KimCHKimHKRettigRLmiRNA signature associated with outcome of gastric cancer patients following chemotherapyBMC Med Genomics479200110.1186/1755-8794-4-79 BroxtermanHJGotinkKJVerheulHMUnderstanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinibDrug Resist Updat12114126200910.1016/j.drup.2009.07.00119648052 FojoTMultiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAsDrug Resist Updat105967200710.1016/j.drup.2007.02.00217350322 GattiLZuninoFOverview of tumor cell chemoresistance mechanismsMethods Mol Med111127148200515911977 FanDZhangXChenXBird’s-eye view on gastric cancer research of the past 25 yearsJ Gastroenterol Hepatol20360365200510.1111/j.1440-1746.2005.03797.x15740477 ChumanYSumizawaTTakebayashiYExpression of the multidrug resistance associated protein (MRP) gene in human colorectal, gastric and non-small-cell lung carcinomasInt J Cancer66274279199610.1002/(SICI)1097-0215(19960410)66:2<274::AID-IJC23>3.0.CO;2-B8603824 MatsuhashiNSaioMMatsuoASugiyamaYSajiSThe evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: Time- and p53 expression-dependency of anti-cancer drugsOncol Rep14609615200516077963 NingHLiTZhaoLTRF2 promotes multidrug resistance in gastric cancer cellsCancer Biol Ther5950956200610.4161/cbt.5.8.287716760674 ChangLGuoFWangYMicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoEPathol Oncol Res209398201410.1007/s12253-013-9664-7 YanLHWangXTYangJReversal of multidrug resistance in gastric cancer cells by CDX2 downregulationWorld J Gastroenterol1941554165201310.3748/wjg.v19.i26.4155238647783710417 EitanRKushnirMLithwick-YanaiGTumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patientsGynecol Oncol114253259200910.1016/j.ygyno.2009.04.02419446316 ChenYZuoJLiuYGaoHLiuWInhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cellsChin J Cancer2910061011201010.5732/cjc.010.1023621114921 SchultzJLorenzPGrossGIbrahimSKunzMMicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growthCell Res18549557200810.1038/cr.2008.4518379589 SampsonVBRongNHHanJMicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cellsCancer Res6797629770200710.1158/0008-5472.CAN-07-246217942906 JohnsonSMGrosshansHShingaraJRAS is regulated by the let-7 microRNA familyCell120635647200510.1016/j.cell.2005.01.01415766527 RybakAFuchsHSmirnovaLA feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitmentNat Cell Biol10987993200810.1038/ncb175918604195 YangXJLinXJZhongXMDouble negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cellsCancer Res7094639472201010.1158/0008-5472.CAN-10-2388210451513057570 ChangTCZeitelsLRHwangHWLin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferationProc Natl Acad Sci USA10633843389200910.1073/pnas.0808300106192117922651245 CottermanRKnoepflerPSN-Myc regulates expression of pluripotency genes in neuroblastoma including lif, klf2, klf4, and lin28bPLoS One4e5799200910.1371/journal.pone.0005799194954172686170 MolenaarJJDomingo-FernándezREbusMELIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppressionNat Genet4411991206201210.1038/ng.243623042116 LaurentiEVarnum-FinneyBWilsonAHematopoietic stem cell function and survival depend on c-Myc and N-Myc activityCell Stem Cell3611624200810.1016/j.stem.2008.09.005190417782635113 StantonBRPerkinsASTessarolloLSassoonDAParadaLFLoss of Nmyc function results in embryonic lethality and failure of the epithelial component of the embryo to developGene Dev622352247199210.1101/gad.6.12a.2235 KonoplevaMTabeYZengZAndreeffMTherapeutic targeting of micro environmental interactions in leukemia: mechanisms and approachesDrug Resist Updat12103113200910.1016/j.drup.2009.06.001196328873640296 VoulgariAPintzasAEpithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinicBiochim Biophys Acta17967590200919306912 WangZLiYBanerjeeSSarkarFHEmerging role of Notch in stem cells and cancerCancer Lett279812200910.1016/j.canlet.2008.09.0302699045 WangZWLiYWAhmadATargeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistanceDrug Resist Updat13109118201010.1016/j.drup.2010.07.001206922002956795 AhmedNAbubakerKFindlayJQuinnMCancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistanceJ Cell Biochem1142134201310.1002/jcb.24317

IC50 of DDP, VCR, 5-FU and expression of let-7b and c-Myc in gastric cancer cells. (A) SGC7901, SGC7901/VCR, SGC7901/DDP cells were seeded in 96-well plates for 24 h and then treated with different concentrations of DDP, VCR and 5-FU. After 48 h, the absorbance at 490 nm was measured on an ELISA reader. Dose-effect curves of anticancer drugs were drawn and IC50 values were determined; (B) Expresion of let-7b and c-Myc mRNA in SGC7901, SGC7901/VCR, SGC7901/DDP cells were analyzed by quantitive PCR (*P<0.01, vs. SGC7901 cells); (C) Expresion of c-Myc protein was evaluated by western blotting; (D) The relative expression of c-Myc protein was higher in SGC7901/DDP and SGC7901/VCR cells (*P<0.01, vs. SGC7901 cells).

Let-7b regulates the expression of c-Myc by directly targeting 3′UTR. (A) A conserved let-7 binding site in the c-Myc 3′UTR was detected by TargetScan. (B) The c-Myc 3′UTR reporter assay showed that transfection of a let-7b mimic significantly reduced the luciferase activity in the wild-type but not the let-7 binding site mutant c-Myc 3′UTR reporters (*P<0.01).

Transfection of let-7b mimic downregulates the expression of c-Myc both at mRNA and protein levels in SGC7901/DDP and SGC7901/VCR cells, increasing the sensitivity of chemotherapy. (A) Expression of let-7b was significantly higher in the two cells after let-7b mimic transfection. By contrast, the expression of c-Myc was significantly lower in the two cells after let-7b mimic transfection (*P<0.05). (B) The results of western blotting show that transfection of let-7b mimic significantly downregulates the expression of c-Myc protein in the two cells. (C) MTT assay show that the cell viability was reduced significantly in the two cells after transfection with the let-7b mimic at 48 and 72 h as compared with the control mimic (*P<0.05). (D) IC50 values of DDP, VCR and 5-FU were determined in the two cells by MTT assay and were downregulated by let-7b mimic transfection (*P<0.05).

Transfection of let-7b inhibitor upregulates the expression of c-Myc at the mRNA and protein levels in SGC7901 cells and decreases the sensitivity of chemotherapy. (A) Expression of let-7b was significantly decreased in SGC7901 cells after let-7b inhibitor transfection. By contrast, the expression of c-Myc was significantly higher after let-7b mimic transfection. (*P<0.05). (B) The results of western blotting show that transfection of let-7b inhibitor significantly upregulates the expression of c-Myc protein. (C) MTT assay show the cell viability was increased significantly in SGC7901 cells after transfection with the let-7b mimic at 48 and 72 h as compared with the control mimic (*P<0.05). (D) IC50 values of DDP, VCR and 5-FU were determined by MTT assay and were upregulated by let-7b inhibitor transfection (*P<0.05).

A possible model. Our present findings together with previous studies support a model in which double-negative autoregulatory loops (Lin28/let-7 and Myc/let-7) and a double-positive autoregulatory loop (Lin28/Lin28B/Myc) existing in gastric cancer cells may control cancer stem cell differentiation and regulate MDR.

Primer sequences for real-time PCR.

Gene Primer sequence
Pre-let-7 F: TGA GGT AGT AGG TTG TGT GGTR: GGA AGG CAG TAG GTT GTA TAG
U6 F: CTC GCT TCG GCA GCA CAR: AAC GCT TCA CGA ATT TGC GT
c-Myc F: CCC AGC GAG ACA TCT GGA AGA AR: GAG AAG CCG CTC CAC ATG CAG TC
Actin F: AAG GTG AAG GTC GGA GTC AACR: GGG GTC ATT GAT GGC AAC AATA

F, forward; R, reverse.